Trial Profile
Voraxapar in healthy Caucasian subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Nov 2015
Price :
$35
*
At a glance
- Drugs Vorapaxar (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 29 Nov 2015 New trial record